早产儿应用尖吻蝮蛇血凝酶止血的安全性评价

A research on the safety of haemocoagulase agkistrodon application in premature infant

目的评价早产儿使用尖吻蝮蛇血凝酶止血的安全性。方法50例早产儿入院后第1天给予尖吻蝮蛇血凝酶0．5单位，静脉注射，1OE／a，连续使用7～10d，观察用药前后机体的凝血功能、生命体征及肝肾功能等指标。结果50例凝血功能异常的早产儿用药前凝血酶原时间（PT）为（31±5）s，用药后为（23±4）s，用药前后差异有统计学意义（P〈0．05），用药后患儿PT时间缩短，对患儿的其他凝血功能指标不产生影响，并且其生命体征、肝、肾、心脏及血常规均未发生显著性变化。结论早产儿使用尖吻蝮蛇血凝酶有较高的安全性。

Objective To evaluate the safety of the application of hemocoagulase agkistrodon in preterm infant. Methods Fifty premature infants were administrated with haemocoagulase agkistrodon with the dosage of O. 5 units for 7 to 10 days. The coagulation function and safety index before operation and after administration were observed. Results There was a significant difference of prothrombin time （PT） in these infants before and after the administration of haemocoagulase agkistrodonl （ 31±5 ） s vs （ 23 ± 4 ） s, P 〈 O. 051. There were no significant differences of the vital sign, the function of organs and other coagulation parameters. No adverse events occurred in the research. Conclusion The application of haemocoagulase agkistrodon is safe in premature infant.